Disparities between NCCN guideline-concordant treatment and actual care were most likely to occur in two patient populations.
Although this study was closed early because findings from an unplanned analysis suggested futility, the final analysis did not support that conclusion.
Patterns of genetic alterations could guide management.
A quality improvement project achieved significant improvements in documentation and treatment planning after nurse assessments were included in provider care notes templates.
Patients with NSCLC who did not respond to immune checkpoint blockade had unique molecular characteristics, revealing possible therapeutic targets.
In this study, researchers identified 8 common themes related to challenges patients experience with ostomy self-management.
Approval was based on data from a phase 2 trial that evaluated the safety and efficacy Brukinsa in 86 patients with MCL.
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
A cross-sectional survey examined Medical Expenditure Panel Survey data on prescriptions for gabapentinoid medications given for pain management in patients with cancer.
Plant-based diets might lower risk, animal-based diets containing dairy might raise risk for prostate cancer
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Non-IgM monoclonal gammopathy was found to have an effect on progression-free survival and overall survival for patients with diffuse large B-cell lymphoma.
A retrospective cohort analysis found that patients with DLBCL who experienced infusion reactions during treatment with rituximab had prolonged overall survival. In addition, progression-free survival was affected in subsets of patients with DLBCL.
Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.